FLAG方案诱导化疗初治急性单核细胞白血病的临床观察

杨斌; 王彪; 董伟民; 曹祥山

doi:10.13201/j.issn.1004-2806.2012.06.008

FLAG方案诱导化疗初治急性单核细胞白血病的临床观察

- 常州市第一人民医院苏州大学附属第三医院血液科(江苏常州, 213003)

详细信息

通讯作者: 杨斌,E-mail:yangbinwang@sohu.com

中图分类号: R733.71

收稿日期: 2012-01-22

Clinical study of FLAG regimen as induction chemotherapy in the treatment of newly diagnosed acute monocytic leukemia patients

- Department of Hematology, The First People's Hospital of Changzhou, The Third Affiliated Hospital of Soochow of University, Changzhou, 213003, China

More Information

Corresponding author: YANG Bin, E-mail: yangbinwang@sohu.com

Received Date: 22 January 2012

摘要

摘要: 目的:初步探讨 FLAG 方案在初治急性单核细胞白血病(M₅)诱导化疗中的临床疗效和不良反应。方法:10 例初治 M₅患者,采用 FLAG 方案诱导化疗,具体用法为氟达拉滨(Flud)30 mg · m^-2 · d^-1,持续静脉滴注 30 min,第1 ~ 5天;阿糖胞苷(Ara-C)1 g · m^-2 · d^-1,Flud 结束后4 h开始,持续静脉滴注 4 h,第1~ 5天;粒细胞集落刺激因子(G-CSF)5 μ g · kg^-1 · d^-1,皮下注射,第0~5天。以完全缓解率(CR)和有效率及不良反应作为观察指标。结果:1 个疗程 FLAG 方案诱导化疗患者 CR 率为80%,有效率为90%。化疗的不良反应主要为骨髓抑制和粒细胞缺乏所致的感染,未见严重的非血液系统不良反应。结论:FLAG 方案诱导化疗初治急性单核细胞白血病患者具有较高的 CR 率,不良反应可耐受。
- 白血病,单核细胞性,急性 /
- FLAG 方案 /
- 诱导化疗
Abstract: Objective:To primarily evaluate the clinical efficacy and adverse reaction of FLAG regimen as induction chemotherapy for newly diagnosed patients with acute monocytic leukemia(M₅).Method:Ten cases of de novo adult AML M₅ were treated with FLAG regimen as induction chemotherapy which included fludarabine 30 mg·m^-2·d^-1 over 30 min daily for 5 days and Ara-C 1 g·m^-2·d^-1 for 5 days over 4 hours starting after 4 hours after completion of daily fludarabine.G-CSF 5 μg·kg^-1·d^-1 subcutaneously daily on days 0 to 5.The complete remission(CR)rate and the overall response rate and adverse reactions were studied.Result:After one course of FLAG regimen as induction chemotherapy,the CR rate in 10 patients was 80%(8/10),the overall response rate was 90%(9/10).Myelosuppression and infections due to neutropenia were the most common adverse effects and severe nonhematologic toxicity was not observed.Conclusion:FLAG regimen achieves higher CR rate for newly patients with M₅ with acceptable toxicity.It is therefore worthy of popularization as induction chemotherapy for newly diagnosed patients with M₅.
- leukemia,monocytic,acute /
- FLAG regimen /
- induction chemotherapy

HTML全文

参考文献(15)

[1]	ZWAAN C M,KASPERS G J,PIETERS R,et al.Cellular drug resistance profiles in childhood acute myeloid leukemia:differences between FAB types and comparison with acute lymphoblastic leukemia[J].Blood,2000,96:2879-2886.
[2]	TALLMAN M S,KIM H T,PAIETTA E,et al.Acute monocytic leukemia(French-American-British classification M₅)does not have a worse prognosis than other subtypes of acute myeloid leukemia:a report from the Eastern Cooperative Oncology Group[J].J Clin Oncol,2004,22:1276-1286.
[3]	JACKSON G,TAYLOR P,SMITH G M,et al.A multicentre,open,noncomparative phase II study of a combination of fludarabine phosphate,cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukemia and de novo refractory anaemia with excess of blasts in transformation[J].Br J Haematol,2001,112:127-137.
[4]	黄晓军,路瑾,陆道培.氟达拉宾为主方案治疗难治复发急性白血病[J].中华内科杂志,2003,42(6):417-419.
[5]	华东FLAG方案治疗协作组.氟达拉滨联合阿糖胞苷和粒细胞集落刺激因子治疗复发和难治性急性髓系白血病[J].中华血液学杂志,2005,26(11):684-685.
[6]	肖音,黎纬明,邹萍.FLAG方案治疗难治性急性白血病47例临床观察[J].临床血液学杂志,2009,22(6):592-594.
[7]	张之南,沈悌.血液病诊断及疗效标准[M].3版.北京:科学出版社,2007:103-134.
[8]	周学慧,肖志坚.国际工作组关于急性髓系白血病治疗试验的诊断、疗效标准的标准化、治疗结局和报告标准的修订建议[J].白血病·淋巴瘤,2004,13(4):246-250.
[9]	BASHEY A,LIU L,IHASZ A,et al.Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older[J].Leuk Res,2006,30:503-506.
[10]	HUBEEK I,LITVINOVA E,PETERS G J,et al.The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia[J].Int J Oncol,2004,25:1823-1829.
[11]	葛晋源.HA方案治疗16例急性单核细胞性白血病疗效观察[J].白血病·淋巴瘤,2005,14(5):311-312.
[12]	秦彦,王全顺,于力.MA与DA方案诱导缓解急性单核细胞白血病的疗效比较[J].山西医药杂志,2009,38(8):743-745.
[13]	杨军,刘晓力.IDA方案治疗不同遗传学危险组急性髓系白血病M4/M₅型临床疗效的比较[J].南方医科大学学报,2010,30(6):1439-1442.
[14]	KANTARJIAN H,WANG X,PLUNKETT W K,et al.Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine,cytarabine,and granulocyte colony-stimulating factor results in improved event-free survival[J].Cancer,2008,113:3181-3185.
[15]	HAFERLACH T,SCHOCH C,SHNITIGER S,et al.Distinct genetic patterns can be identified in acute monoblastic and acute monocytic leukemia(FAB AML M₅a and M₅b):a study of 124 patients[J].Br J Haematol,2002,118:426-431.